Cost-effectiveness analysis of Mammostrat ® compared with Oncotype DX ® to inform the treatment of breast cancer

Purpose To compare the cost-effectiveness of the tumor subtyping assays Mammostrat® and Oncotype DX® for assessing risk of recurrence in early-stage breast cancer and the potential benefit of adjuvant chemotherapy.